Pazdur Calls For 'Kumbaya’ To Standardize ImmunoOncology Biomarkers

 
• By Sarah Karlin-Smith

The US FDA Oncology Center of Excellence head also urged companies to commit to offer their PD-L1 drugs to certain patients free of charge via compassionate use if the gastric and esophageal cancer labeling is modified.

Diverse group of business people coming together in a corporate huddle, stacking their hands together as they stand in an office.
Pazdur said drug sponsors must collaborate on immunology biomarkers moving forward. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers